Scientech Research LLC’s Plus Therapeutics PSTV Stock Holding History

Scientech Research LLC’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,866	Closed	-$100K	–	744
2025 Q3	$100K	Buy	+5,866	New	+$72K	0.03%	498

Other funds holding PSTV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

L1 Global Manager Melbourne $149M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Scientech Research LLC's PSTV Position: Q4 2025 in Review

Scientech Research LLC sold out of Plus Therapeutics (PSTV) in Q4 2025, closing a stake of 5,866 shares — an estimated $100K sold.

Scientech Research LLC first reported a position in PSTV in Q3 2025 and held it in 1 quarter. The position peaked at $100K in Q3 2025. 25 funds tracked by Wall St. Rank hold PSTV as of Q4 2025.

Scientech Research LLC reported no remaining Plus Therapeutics position as of Q4 2025 after selling out during the quarter.
Scientech Research LLC sold 5,866 Plus Therapeutics shares in Q4 2025, an estimated $100K.
Scientech Research LLC first reported a position in Plus Therapeutics in Q3 2025 and held it in 1 quarter.
Scientech Research LLC's Plus Therapeutics position peaked at $100K in Q3 2025.
25 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2025.

Based on Scientech Research LLC's 13F filing for Q4 2025, filed 17 Feb 2026.